• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    What Alumis (ALMS)'s Envudeucitinib Phase 3 Data and Deepening Losses Means For Shareholders

    Simply Wall St·08/19/2026 01:22:51
    Listen to the news
    • Earlier in August 2026, Alumis Inc. reported second-quarter results showing revenue of US$1.66 million and a net loss of US$142.22 million, reversing a net profit a year earlier as loss per share widened sharply.
    • A few days before that earnings release, Alumis reported positive topline Phase 3 ONWARD3 extension data for its oral TYK2 inhibitor envudeucitinib in plaque psoriasis and outlined plans to file a U.S. FDA New Drug Application this year, highlighting a potential first-in-class, high-efficacy oral option for immune-mediated diseases.
    • We will now examine how envudeucitinib’s Phase 3 ONWARD3 results and upcoming FDA filing shape Alumis’s investment narrative and risk profile.

    Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.

    What Is Alumis' Investment Narrative?

    To own Alumis today, you have to believe that envudeucitinib can move from strong clinical data to an approved, commercially relevant oral option for immune-mediated diseases, while the company manages heavy losses and dilution risk. The ONWARD3 extension results and the plan to file an FDA NDA this year sharpen the story: they reinforce envudeucitinib as the key near term catalyst, but also raise the stakes around regulatory review and future commercialization execution. At the same time, the latest quarter’s revenue decline to US$1.66 million and a much larger net loss of US$142.22 million underline how dependent the equity case is on successful drug approval and partnering or launch. With the share price already up very sharply year to date, expectations around these milestones look especially important.

    Our comprehensive valuation report raises the possibility that Alumis is priced higher than what may be justified by its financials.

    Exploring Other Perspectives

    ALMS 1-Year Stock Price Chart
    ALMS 1-Year Stock Price Chart

    One Simply Wall St Community member pegs fair value at US$40.33 per share, before factoring in the latest ONWARD3 and earnings news. You can weigh that single viewpoint against the heightened regulatory and cash burn risks now shaping Alumis’s trajectory and consider how different assumptions might affect your own assessment.

    Explore another fair value estimate on Alumis - why the stock might be worth as much as 62% more than the current price!

    The Verdict Is Yours

    Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Ready For A Different Approach?

    Our top stock finds are flying under the radar-for now. Get in early:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.